【摘要】 目的 探讨阿戈美拉汀联合碳酸锂缓释片治疗双相抑郁的疗效研究。方法 按照DSM-5标准，纳入86例双相抑郁患者，按照随机数字法将患者分配至治疗组和对照组，治疗组给予碳酸锂缓释片+阿戈美拉汀，对照组给予碳酸锂缓释片，随访12周。结果 两组之间17项汉密尔顿抑郁量表减分率，在2周、4周、8周、12周访视期均存在差异，治疗组减分率均高于对照组（P<0.01）；且在治疗第8周时，治疗组缓解率（100%）高于对照组（11.3%）。两组的匹兹堡睡眠量表评分在各访视期均存在显著差异。联合治疗组第3周、6周、12周外周血谷丙转氨酶、谷草转氨酶水平有变化，但各访视期总体均值均在正常范围（<40U/L）。结论 阿戈美拉汀联合碳酸锂缓释片治疗双相抑郁可以快速缓解抑郁症状，并改善睡眠症状，可为今后双相抑郁发作优化治疗提高参考。更多还原

【Abstract】 Objective To investigate the efficacy of agomelatine combined with mood stabilizer in the treatment of bipolar depression. Methods A total of 86 patients with bipolar depression who were treated in our hospital from September 2019 to November 2020 were recruited. Pateints were distributed into two groups,the "treatment group" and the "control group" according to the random number method. The treatment group was treated with lithium sustainedrelease tablets combined with agomelatine,and the control group was treated with lithium only,and follow-up for 12weeks. Results The outcome of the treatment group was significantly higher than that of the control group(P<0.05).The reduction rate of Hamilton Depression Rting Scale-17,of the treatment group was higher than that of the control group at the visit of 2 weeks,4 weeks,8 weeks,and 12 weeks(P<0.01). The remission rate of the treatment group(100%)was significantly higher than that of the control group(11.3%)at the 8th week of treatment. There were significant differences in the PSQI scores between the two groups in each visit. Though the levels of ALT and AST in the peripheral blood of patients of the treatment group were different at different follow-up periods(P<0.01). The mean value of each visiting period was still in the normal range(<40U/L). Conclusion Agomelatine combined with a mood stabilizer(lithium carbonate)in the treatment of bipolar depression can quickly relieve depressive symptoms,improve sleep. We didn’t find specific hepatic dysfunction while combined with Agomelatine. This new medication strategy may optimize the treatment of bipolar depression in the future.更多还原